PHVS fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
PHVS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company